Avalo Therapeutics, Inc. (AVTX)
Automate Your Wheel Strategy on AVTX
With Tiblio's Option Bot, you can configure your own wheel strategy including AVTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AVTX
- Rev/Share 0.0419
- Book/Share 11.6611
- PB 0.4082
- Debt/Equity 0.0
- CurrentRatio 22.6075
- ROIC -0.3787
- MktCap 51539376.0
- FreeCF/Share -4.9749
- PFCF -0.9852
- PE 0.6855
- Debt/Assets 0.0
- DivYield 0
- ROE 1.0636
- Rating A
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | AVTX | H.C. Wainwright | -- | Buy | -- | $15 | June 2, 2025 |
| Initiation | AVTX | Jefferies | -- | Buy | -- | $23 | March 25, 2025 |
| Initiation | AVTX | Stifel | -- | Buy | -- | $36 | March 25, 2025 |
| Initiation | AVTX | Piper Sandler | -- | Overweight | -- | $48 | Feb. 28, 2025 |
| Initiation | AVTX | Wedbush | -- | Outperform | -- | $18 | Feb. 21, 2025 |
| Initiation | AVTX | BTIG Research | -- | Buy | -- | $40 | Dec. 19, 2024 |
News
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Published: May 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
WAYNE, Pa. and ROCKVILLE, Md., May 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in June.
Read More
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and financial results for the first quarter of 2025.
Read More
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors (“Board”). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company.
Read More
Avalo Reports 2024 Financial Results and Recent Business Updates
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md.
Read More
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
WAYNE, Pa. and ROCKVILLE, Md., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced that management will participate in the following investor conferences in March.
Read More
About Avalo Therapeutics, Inc. (AVTX)
- IPO Date 2015-10-14
- Website https://www.avalotx.com
- Industry Biotechnology
- CEO Dr. Garry A. Neil M.D.
- Employees 23